[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2184808T3 - Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12. - Google Patents

Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12.

Info

Publication number
ES2184808T3
ES2184808T3 ES95933488T ES95933488T ES2184808T3 ES 2184808 T3 ES2184808 T3 ES 2184808T3 ES 95933488 T ES95933488 T ES 95933488T ES 95933488 T ES95933488 T ES 95933488T ES 2184808 T3 ES2184808 T3 ES 2184808T3
Authority
ES
Spain
Prior art keywords
phenylalanine
combination
multiple sclerosis
demelinizing
triptophan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933488T
Other languages
English (en)
Inventor
Cari Loder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420116A external-priority patent/GB9420116D0/en
Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2184808T3 publication Critical patent/ES2184808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)

Abstract

EL USO DE UNA COMBINACION DE UN ANTIDEPRESOR TRICICLICO O TETRACICLICO , UN INHIBIDOR DE LA RECAPTACION DE SEROTONINA, O UN INHIBIDOR DE LA OXIDASA MONOAMINO CON UN INDUCTORNEUROTRANSMISOR O COMPUESTO PRECURSOR ESTA PENSADO PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PREVENCION DE LA ESCLEROSIS MULTIPLE U OTRAS AFECCIONES DESMIELINIZANTES. EN EL USO DEL TRATAMIENTO DE MEJORA DE LOS EFECTOS DE UNA AFECCION DESMIELINIZANTE , SE CONSIDERA UN REGIMEN DIARIO DE 10 A 220 MG. DE LOFEPRAMINA Y DE 100 MG. A 5 G DE L-FENILALANINA, SUPLEMENTADO DIARIAMENTE CON INYECCIONES DE VITAMINA B{SUB,12}.
ES95933488T 1994-10-05 1995-10-05 Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12. Expired - Lifetime ES2184808T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en) 1995-04-26 1995-04-26 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product

Publications (1)

Publication Number Publication Date
ES2184808T3 true ES2184808T3 (es) 2003-04-16

Family

ID=26305745

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933488T Expired - Lifetime ES2184808T3 (es) 1994-10-05 1995-10-05 Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12.

Country Status (19)

Country Link
US (2) US6096737A (es)
EP (1) EP0784476B1 (es)
JP (1) JPH10508583A (es)
AT (1) ATE227124T1 (es)
AU (1) AU710339B2 (es)
CA (1) CA2200761C (es)
CZ (1) CZ293873B6 (es)
DE (1) DE69528773T2 (es)
DK (1) DK0784476T3 (es)
ES (1) ES2184808T3 (es)
FI (1) FI116659B (es)
HU (1) HU225493B1 (es)
IS (1) IS1956B (es)
NO (1) NO314486B1 (es)
NZ (1) NZ293642A (es)
PL (1) PL181802B1 (es)
PT (1) PT784476E (es)
SK (1) SK281932B6 (es)
WO (1) WO1996011009A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335323B2 (en) * 1996-07-05 2002-01-01 The Wwk Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin B12 and/or precursors or inducers of a neurotransmitter
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) * 1999-02-24 1999-04-21 Worsley Andrew P Composition for the treatment of pain
GB9906808D0 (en) * 1999-03-24 1999-05-19 Kilgowan Limited Formulation for treatment of pain
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) * 2002-03-14 2004-12-21 Duane Bennett Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
NZ539735A (en) 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
EP1599212A4 (en) * 2003-02-14 2006-02-08 Combinatorx Inc POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
EP2517718B1 (en) * 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
US20110136742A1 (en) * 2006-02-24 2011-06-09 Travis Mickle Antidepressant prodrugs
JP5856843B2 (ja) * 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
CN103841987B (zh) 2011-10-10 2015-06-17 安皮奥制药股份有限公司 退行性关节病的治疗
BR112014007657A2 (pt) 2011-10-10 2017-04-11 Ampio Pharmaceuticals Inc dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
SG10201707619RA (en) 2013-03-15 2017-10-30 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EP3183240A4 (en) 2014-08-18 2018-06-27 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES
GB2544630A (en) 2015-11-19 2017-05-24 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
CA3041358A1 (en) * 2016-10-25 2018-05-03 Uti Limited Partnership Treatment for progressive multiple sclerosis
WO2018200381A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (en) * 2017-07-18 2019-01-23 Centre National De La Recherche Scientifique Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497306A (en) * 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4409243A (en) * 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) * 1992-02-12 1998-09-24 Kragler Peter Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

Also Published As

Publication number Publication date
DE69528773T2 (de) 2003-09-04
US6569850B1 (en) 2003-05-27
NO971539L (no) 1997-04-04
WO1996011009A1 (en) 1996-04-18
DE69528773D1 (de) 2002-12-12
SK43897A3 (en) 1998-08-05
HUT77380A (hu) 1998-04-28
IS4454A (is) 1997-03-26
CZ293873B6 (cs) 2004-08-18
JPH10508583A (ja) 1998-08-25
PL319830A1 (en) 1997-09-01
CZ99597A3 (en) 1997-11-12
CA2200761A1 (en) 1996-04-18
DK0784476T3 (da) 2003-03-17
PL181802B1 (en) 2001-09-28
SK281932B6 (sk) 2001-09-11
NZ293642A (en) 1998-10-28
EP0784476A1 (en) 1997-07-23
CA2200761C (en) 2008-02-26
IS1956B (is) 2004-11-15
NO314486B1 (no) 2003-03-31
EP0784476B1 (en) 2002-11-06
FI116659B (fi) 2006-01-31
AU3612695A (en) 1996-05-02
HU225493B1 (en) 2007-01-29
AU710339B2 (en) 1999-09-16
PT784476E (pt) 2003-03-31
FI971290A0 (fi) 1997-03-26
ATE227124T1 (de) 2002-11-15
FI971290A (fi) 1997-06-02
US6096737A (en) 2000-08-01
NO971539D0 (no) 1997-04-04

Similar Documents

Publication Publication Date Title
ES2184808T3 (es) Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12.
EP0687175A4 (en) METHOD OF TREATING EMOTIONAL OR MENTAL ILLNESS, AND EMOTIONAL OR MENTAL ILLNESS CONCURRENT TO CRISIS
UA32429C2 (uk) Засіб для лікування нетримання сечі
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
ES2175437T3 (es) Composicion de enalapril y losartan.
NO984197L (no) FremgangsmÕte for behandling av autisme
PL329219A1 (en) Application of benzonaphtene derivatives in production of drugs for treating nervous system diseases
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
KR960003741A (ko) 조골세포 증식인자
ES2183977T3 (es) Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
EA199800818A1 (ru) Способ лечения бессонницы
CO4700451A1 (es) Dimaleato de n,n-dietil-8, 8-dipropil-2-azaspiro[4.5] decano-2-propanamina
UA10254A (uk) Спосіб лікування цукрового діабету
UA32580C2 (uk) Засіб для лікування паралітичної непрохідності кишечнику
UA29025A (uk) Спосіб лікування ендокринної неплідності
UA30659A (uk) Спосіб купіровання опіатної залежності
MD950121A (ro) Metodă de tratare a urmărilor ictusurilor ischemice
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
WO2000067733A3 (de) Medikament zur therapie der männlichen infertilität
RU94033502A (ru) Способ лечения детей, больных вторичным панкреатитом